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Effects of oxygen breathing and erythropoietin on hypoxic vasodilation
in uremic anemia. Loss of hypoxic vasodilation has been proposed as a
causative factor in the development of hypertension in dialysis patients
treated with recombinant human erythropoietin (rHuEPO). Venous
occlusion plethysmography was therefore performed on 22 dialysis
patients (aged 23 to 71 years, dialysis duration 6 to 260 months, 8 males)
before and after correction of anemia with rHuEPO, 50 U/kg 3 x/week
(Hb: 7.4 0.3 vs. 10.8 0.3 g/dl, P < 0.0001). Hypertension (> 15 mm
Hg rise in mean BP) occurred in 11 patients. The study was performed
while breathing room air and repeated after breathing 60% 02 for 10 to
12 minutes. Before rHuEPO therapy, total blood 02 content increased
from 10.01 0.39 to 10.32 0.29 ml 02/100 ml blood with breathing
60% 02 (P < 0.01). After correction of anemia it was 14.65 0.40 ml
02/100 ml blood on room air (P < 0.001). There was a significant
decrease in forearm blood flow (7.9 0.5 vs. 6.5 0.6 ml/min/100 ml
tissue, P < 0.05) and increase in forearm vascular resistance (12.8 0.1
vs. 16.8 0.2 mm Hg/ml/minIlOO ml tissue, P < 0.05) with 02 breathing
prior to rHuEPO therapy in the blood pressure responders, but no
change in these parameters in the group in which blood pressure
remained unchanged. When all patients were studied on room air,
forearm vascular resistance rose significantly after correction of anemia
(13.0 0.8 vs. 16.3 0.8 mm Hg/ml/min/l00 ml tissue, P < 0.05),
compared with that prior to rHuEPO therapy. However, no difference
in this increase was detected between blood pressure responders and
non-responders. In conclusion, forearm vascular resistance increases in
uremic anemia in response to increased delivery of 02, suggesting the
existence of significant hypoxic vasodilation. The reversal of hypoxic
vasodilation achieved by increased P°2 is greater in patients in whom
blood pressure increases during correction of anemia. The enhanced
vascular reactivity to reversal of low blood oxygen content present in
these patients may partly account for the development of hypertension.
Recombinant human erythropoietin (rHuEPO) has revolu-
tionized the management of uremic anemia in both pre-dialysis
and dialysis patients. However, a common side effect of cor-
rection of anemia is the development of hypertension [1, 2]. In
the dialysis population this has been reported in approximately
one-third of patients [3]. Investigation of the etiology of eryth-
ropoietin-induced hypertension has previously been directed
toward the increases in whole blood viscosity and in systemic
vascular resistance which occur as hematocrit rises. There is a
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rise in whole blood viscosity in all patients which is in propor-
tion to the increment in red cell count [4].
The increase in whole blood viscosity with rHuEPO therapy
cannot fully account for the elevation of vascular resistance
which occurs, and loss of hypoxic vasodilatation may also be an
important factor [5]. Changes in regional vascular resistance
following rHuEPO therapy have been assessed by means of
venous occlusion plethysmography which has shown incre-
ments ranging from 37 to 49% [6] to 79% [7], associated with an
increase in transcutaneous oxygen pressure [7]. Tissue hypoxia
itself causes vasodilation, presumably through release of local
metabolic factors, and thus improvement in tissue oxygenation
will reduce vasodilation independent of increases in hematocrit
and viscosity.
Hemodynamic studies have also shown that systemic vascu-
lar resistance increases in all patients receiving rHuEPO,
whether or not they become hypertensive [7—9]. The purpose of
this study was to determine if patients developing an increase in
blood pressure are distinguishable by an altered vascular re-
sponse, assessed by plethysmography, to correction of hypoxic
vasodilation by inspiration of supplementary oxygen, or to
reversal of uremic anemia with rHuEPO therapy.
Methods
Patients
Twenty-two consecutive patients requiring rHuEPO for ane-
mia were studied. Their clinical details are listed in Table 1.
Nine of these were receiving maintenance hemodialysis ("Cen-
trysystem 3", Cobe) two or three times per week for a total of
12 to 15 hours, using hollow fiber dialyzers ("AM-1SOH" or
"AM-200M", Asahi Med. Co.). None suffered from dialysis-
induced hypotension. The remaining patients were receiving
continuous ambulatory peritoneal dialysis, treated with four
exchanges per day of 1.5 to 2.0 1 volume and 1.36, 2.27 or 3.86%
wt/vol concentration of glucose ("Dianeal", Baxter, UK).
Eleven patients were on anti-hypertensive medication at the
time of commencing rHuEPO and this was stopped at least 72
hours before assessment. No patients smoked. All patients
were receiving treatment as required with calcium carbonate,
aluminium hydroxide and la-vitamin D.
All patients were anemic (Hb < 8.1 g/dl) at the beginning of
the study. Deficiencies of iron, B12 and folic acid were ex-
cluded. Patients were commenced on rHuEPO ("Eprex", Cilag
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Table 1. Clinical features of patients who maintained a stable blood
pressure (Group 1) and those who manifested a rise in blood pressure
(Group 2) during treatment with rHuEPO
Group I Group 2
(W= 11) (N= 11)
Age years 45.5 4.5 40.9 3.5
Dialysis time monthsb 110 23 41 11
Sex
Male 4 4
Female 7 7
Dialysis type
Hemodialysis 4 5
CAPD 7 6
Diagnosis
Glomerulonephritis 7 5
Hypertension — 4
Diabetes mellitus — I
SLE — I
Reflux nephropathy 1 —
TB 1 —
Undefined 2 —
Anti-hypertensive medications
ACE inhibitors I 8
/3-blockers 0 2
Calcium antagonists 1 7
Hemoglobin gidi
Initial 7.2 0.3 1 7.5 0.3 1
Final 10.9 02bj 10.8 04b1
Mean blood pressure mm Hg
Initial 93.9 3.1 109.3 6.4 1
Maximum on rHuEPO 95.5 3.0 123.5 4.2")
at time of
plethysmography
Initial 91.2 5.0 105.4 4.2
Final 85.0 4.5 b_ 108.6 2.8
Biotech, UK) at an initial dose of 50 U/kg, administered three
times per week either subcutaneously or intravenously. The
dose of rHuEPO was adjusted to maintain a target hemoglobin
between 10.0 and 11.0 g/dl.
A significant increase in blood pressure was defined as a
greater than 15 mm Hg rise in mean blood pressure (diastolic
pressure plus one-third pulse pressure) on more than two
occasions during the treatment period. Blood pressure re-
mained stable in 11 patients (Group 1) and increased in the other
11 treated patients (Group 2).
Methods
Studies were performed in the morning, and on the day
following dialysis for hemodialysis patients. All studies were
performed in a well lit examination room maintained at a steady
temperature for all testing. Patients were investigated before
commencement of rHuEPO and studies were repeated as soon
as possible after the time of attainment of the target hemoglobin
response (10.0 to 11 g/dl).
Blood flow was estimated by venous occlusion plethysmog-
raphy [10, 11] in the forearm of the non-fistula arm. A mercury
in silastic rubber strain gauge (E. Hokanson) was positioned at
the point of maximum circumference below the antecubital
space. Patients were supine and the forearm rested by the side,
just above heart level. The gauge was connected to a plethys-
mograph (EC-3 Plethysmograph, D.E. Hokanson) and results
recorded on a chart recorder (Model MX2R-223, Devices
Instruments Ltd.). Venous occlusion was obtained by rapid
inflation of a 12 cm pneumatic cuff, attached to the upper arm
above the elbow, to a pressure of 40 mm Hg (E-10 Rapid Cuff
Inflator, D.E. Hokanson). A pediatric cuff was applied at the
wrist, inflated to 200 mm Hg one minute before blood flow
measurements and maintained to arrest circulation to the hand.
Calibration was performed in situ against an electric stimulus
representing a 1% increase in volume. Plethysmographic mea-
surements were recorded for five seconds after inflation of the
venous occlusion cuff. Measurements were made at 10 to 15
second intervals and an average of six recordings were taken.
The average coefficient of variation for the readings was 10.5
0.9%. The forearm circumference was measured and the vol-
ume of the forearm measured by water displacement after
subtracting the hand volume.
The experiment consisted of a 10-minute acclimatization
period followed by measurement of blood flow while the subject
breathed room air at normal atmospheric pressure. Arterial
blood gas determinations were then performed (Model 1312,
Instrumentation Laboratories) after which patients were given
supplementary oxygen for a 15 minute period to provide an
F,02 of 60% (1060 Adult Venturi Mask, Intersurgical). Plethys-
mography was then repeated. At the completion of the second
series of measurements arterial blood gas estimation was re-
peated.
Oxygen content was determined from the hemoglobin con-
centration in blood (Coulter Counter) and arterial and venous
blood partial pressure of oxygen according to the following
formula [12]:
02 content (1.39 x Hb %saturation Hb
ml/dl =
k mug g/dl
X
100
+(00031
Pa02 \
XmmHg)
Blood pressures were measured non-invasively ("Dinamap
845XT", Critikon) before blood flow recordings were made.
The average of three consecutive readings was recorded.
The mean forearm blood flow results are represented in units
of ml/min/lOO ml tissue. Forearm vascular resistance (in units of
mm Hg/ml/min/lOO ml tissue) was obtained by dividing the
mean blood pressure by the forearm blood flow.
Statistical analysis
All results are expressed as mean SEM. Student's (-test was
used for paired and unpaired data. Dichotomous data were
analyzed by chi-square with Yates' correction. Correlations
were assessed by Pearson's linear 'r" test.
Results
Blood pressure and hemoglobin response
Patients were studied before commencement of rHuEPO and
again 15.0 1.7 weeks after treatment began, when the target
hemoglobin was attained. Eleven (50%) of the patients devel-
oped an increase in blood pressure with five requiring initiation
of or increase in anti-hypertensive medication. Maximum mean
blood pressure in both groups during rHuEPO therapy is shown
a p < 0.05, "P < 0.001
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Table 2. Arterial blood gas results before and after correction of
anemia and venous blood gas results before correction of anemia
Group I Group 2
—
Arterial
Oxygen tension mm Hg
Initial—room air 94.5 4.9 96.4 5.26Ø%ob 295±19 275±17
Final—room air 92.1 4.9 89.9 4.2
—60% 02" 273 21 271 22
Hemoglobin saturation %
Initial—room air 96.8 0.5 97.2 0.4
—60% 0b 99.9 0.0 99.9 0.0
Final—room air 97.2 0.4 97.4 0.4
—60% 02" 99.9 0.0 99.9 0.0
pH
Initial—room air 7.375 0.010 7.383 0.016
—60% 02 7.386 0.011 7.379 0.016
Final—room air 7.326 0.009 7.354 0.015
—60% 02 7.341 0.007 7.362 0.019
Venous
Oxygen tension 30.9 3.3 30.5 2.8
Hemoglobin saturation 56.7 5.6 63.6 7.1
pH 7.327 0.0l5a 7.373 0.032
a P < 0.01 vs. pH at room air
b P < 0.001 60% 02 vs. room air
in Table 1. Mean blood pressure increased by 14.8 2.3% in
Group 2 (P <0.001) and remained unchanged in Group 1. Initial
blood pressure tended to be higher in Group 2 than in Group 1
although the difference was not significant. Both groups had a
similar rise in hemoglobin from baseline, reaching target hemo-
globin in similar time periods (15.1 2.7 vs. 14.8 1.8 weeks,
P = NS). There was no difference in sex, age or type of dialysis
between the two groups. Group 1 had been on dialysis for a
longer time period (P < 0.01).
Oxygen content of blood and acid-base change
There was no difference between the two groups in arterial or
venous P°2 or percent saturation of hemoglobin either before
treatment or after rHuEPO therapy, when breathing room air or
supplementary oxygen (Table 2). There was a significant rise in
arterial P°2 with breathing 60% 02 in both groups (P < 0.001).
Before rHuEPO therapy, blood oxygen content was reduced in
both groups as a consequence of anemia (Group 1: 9.78 0.35,
Group 2: 10.28 0.44 ml 02/100 ml blood, P = NS; normal
range: approximately 16.2 to 20.5 ml 02/100 ml blood, assuming
Hb level 12 to 15 g/dl and 97% saturated). Following adminis-
tration of supplementary 60% oxygen, there was a 2.6 1.3%
increase in oxygen content of blood in the whole patient group
with similar increases when Group 1 and 2 were analyzed
separately (Fig. 1). However, breathing supplementary oxygen
resulted in a marked increase in the partial pressure of oxygen
in arterial blood (Table 2). In contrast to the small rise in oxygen
carrying capacity with increased F102, there was a 50.6
26.0% (P < 0.001) rise in oxygen content with correction of
uremic anemia with rHuEPO. Again, there was no difference in
the degree of change between Groups 1 and 2.
In the group that maintained a stable blood pressure, there
was a significant fall in pH across the vascular bed (7.375
0.010 vs. 7.327 0.015, P < 0.01). There was only a small,
non-significant change in pH in the other group (Table 2).
Fig. 1. Changes in oxygen content in response to correction of hypoxia
by supplementary inspired oxygen and correction of uremic anemia
with rHuEPO in all patients combined and separately in Group 1 (stable
BP) and Group 2 (increase in BP during treatment of anemia). Symbols
are: () room air; () 60% oxygen. *D< 0.01, < 0.001.
Fig. 2. Changes in forearm blood flow in response to the correction of
hypoxia by supplementary inspired oxygen and increase in hematocrit
with rHuEPO in all patients combined and then divided into Group 1
(stable BP) and Group 2 (increase in BP during treatment of anemia).
Symbols are: (•) room air; () 60% oxygen. *jD < 0.05.
Forearm blood flow
Following oxygen there was a overall decrease in forearm
blood flow (P < 0.05; Fig. 2). However, when Groups 1 and 2
were analyzed individually, the decrease in flow with increased
oxygen content was significant only in Group 2 (P <0.05).
Blood flow decreased after correction of uremic anemia with
rHuEPO, and this change was of borderline statistical signifi-
cance (1.30 0.78 mI/min/100 ml tissue, P = 0.07). However,
there was no difference between Groups 1 and 2 in the absolute
or percentage change in forearm blood flow after hematocrit
had increased, with or without supplementary oxygen.
Forearm vascular resistance
When all patients were evaluated together before correction
of anemia, supplementary 60% oxygen resulted in a 20.4
7.0% increase in forearm vascular resistance (FVR) (P < 0.05;
Fig. 3). After correction of anemia with rHuEPO, FVR was
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Table 3. Proportion of patients in each group demonstrating changes
in forearm vascular resistance (FVR) following supplementary 02
Change in FVR
Group I Group 2
%
>50% rise 9 27
>30% rise 18 36
>10% rise 45 54
>0% rise 64 81
increased in association with the enhancement of oxygen car-
riage and the increase in hematocrit.
When Groups 1 and 2 were analyzed separately, FVR in-
creased in Group 2 patients in response to oxygen before
rHuEPO therapy, (29.5 12.3%, P < 0.05), but not in Group 1
(11.4 6.6%, P = NS). As with forearm blood flow, FVR was
unchanged by breathing of supplementary oxygen after correc-
tion of anemia.
Although the patients who subsequently became hyperten-
sive demonstrated greater initial changes in blood flow and
vascular resistance following supplementary 02 than those
remaining normotensive, it was not possible to predict from
these changes in which individual patients blood pressure
would increase during rHuEPO therapy. The proportion of
patients demonstrating changes in FVR following supplemen-
tary 02 are shown in Table 3.
There was no correlation between the changes in oxygen
carriage and the changes in forearm blood flow or vascular
resistance.
Discussion
The anemia of chronic renal failure is classically associated
with a state of increased cardiac output [5, 13, 14] and normal
[5] or reduced [15] systemic vascular resistance, adaptive
changes which enable preservation of adequate oxygen supply
to tissues. Neff and colleagues showed that in hypertensive
hemodialysis patients, elevation of the hematocrit over a 6 to 12
week period by blood transfusion resulted in a rise in systemic
vascular resistance and in diastolic and mean blood pressure
[5]. It remains uncertain whether comparable changes occur
when the hematocrit is raised to a comparable degree over two
to three months by administration of rHuEPO. Although similar
increases in hematocrit result from both rHuEPO therapy and
blood transfusion, some investigators have proposed an addi-
tional direct vasoconstrictor influence of rHuEPO on blood
vessels [16], whereas others have failed to demonstrate such an
effect [17, 18].
Poiseulile's law [191 predicts that changes in arteriolar diam-
eter will have a greater effect on vascular resistance than
viscosity. The increase in systemic vascular resistance which
occurs when hematocrit is raised is due to both an increase in
whole blood viscosity and loss of hypoxic vasodilation. The
increase in viscosity is seen at both low and high shear rates,
though is more marked at low shear rate, and is comparable to
the changes which are seen in non-uremic subjects [20, 21]. The
increase in whole blood viscosity has been consistently ob-
served in patients in whom anemia has been corrected with
rHuEPO [20, 22, 23]. Several investigators have also shown
that there is a direct correlation between whole blood viscosity
and total peripheral resistance, whether hematocrit is increased
by transfusion [5] or by rHuEPO [24].
Although these rheological changes (increase in hematocrit
and hence viscosity) consistently result in increased total pe-
ripheral resistance, no association has been found between the
changes in whole blood viscosity and the development of
hypertension in rHuEPO treated patients [24]. In addition,
Williams et a! failed to demonstrate a significant rise in blood
pressure when blood viscosity was acutely raised by blood
transfusion [25]. The same group also examined the effect of a
slower rise in hematocrit and hence whole blood viscosity on
blood pressure. A spontaneous increase in hemoglobin over a
12 month period following the commencement of CAPD failed
to produce an increase in blood pressure. Therefore, although
whole blood viscosity and peripheral resistance are related,
blood viscosity fails to be a clear determinant of blood pressure
in patients with uremia.
The second mechanism by which systemic vascular resis-
tance may increase when hematocrit rises is loss of hypoxic
vasodilation. Increased oxygen tension results in arteriolar
vasoconstriction [26, 27], and several factors may be involved
in this regulation of vascular tone. Animal studies have dem-
onstrated a fall in diffusional transfer of oxygen occurs when the
hematocrit is lowered by hemodilution [28]. Following correc-
tion of uremic anemia, there may be increased vascular reac-
tivity to vasoactive stimuli because of improved tissue oxygen-
ation [241. However, uremia per se does not result in an
increased sensitivity to pressor stimuli [29].
The response to vasoactive stimuli is also influenced by the
baseline degree of vascular contraction [30]. In agreement, in
the present study, addition of supplementary oxygen resulted in
more marked changes in blood flow and vascular resistance
before correction of anemia, when vasodilation was more
marked (Figs. 2 and 3). The changes in gas tension and
Fig. 3. Changes in forearm vascular resistance pre- and post-correc-
tion of uremic anemia with rHuEPO at room air and after supplemen-
tary oxygen in all patients together and divided into Group 1 (stable BP)
and Group 2 (increase in BP during treatment of anemia). Symbols are:
(U) room air; () 60% oxygen. < 0.05.
Resistance = (8 x length) x viscosity(IT x radius4)
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extracellular pH that occur with increased 02 carriage and
hence tissue oxygenation may also result in an increase in
myogenic vascular tone [31—34]. Although increasing hemato-
crit results in a greater rise in blood oxygen content, breathing
supplementary oxygen results both in very high levels of
hemoglobin saturation and an increase in dissolved oxygen in
blood. These combine to produce a situation of hyperoxia
which may alter vascular tone [27]. Finally, it is possible that
the endothelium-derived relaxing factor (nitric oxide) has a role
to play in the changes in arteriolar tone which occur with
increased hematocrit [35], both through greater shear-induced
injury to vessel walls and possibly through increased binding of
nitric oxide by hemoglobin.
In this study we have investigated the effect of reduction of
hypoxia by administration of supplementary oxygen and by
correction of anemia with rHuEPO on forearm blood flow and
vascular resistance in uremic patients. The specific aim was to
determine if there was a difference in response to these two
interventions in patients who maintained a stable blood pres-
sure on rHuEPO treatment and those who developed or expe-
rienced a worsening of hypertension.
Before rHuEPO, administration of 60% 02 resulted in a
reduction in forearm blood flow of 12.1 3.8%. When normal
subjects are administered 100% 02 there is a 23 15% rise in
systemic vascular resistance as derived from direct arterial
measurement of blood pressure and radiolabelled dye dilution
[36]. This effect is also seen when 100% oxygen is breathed by
anemic children [371. In the present study there was a 20.4
6.7% rise in FVR after breathing 60% 02. This compared with
a 36.6 16.7% increase after correction of anemia with
rHuEPO. Although both a fall in blood flow and a rise in
vascular resistance occur with rHuEPO therapy, previous
studies have shown that a net improvement in tissue oxygen-
ation (as measured by skin electrodes) follows these hemody-
namic changes [38].
It has been postulated previously that correction of hypoxic
vasodilation by an increase in the hematocrit may result in a
greater increment in total peripheral resistance in hypertensive
individuals because of the pre-existence of vessel wall damage
[39]. In addition, patients with essential hypertension have
increased hematocrit and whole blood viscosity [40], and a
direct relation between viscosity and blood pressure has also
been seen in a mixed hypertensive and normotensive popula-
tion [41]. In uremia, a relationship has been demonstrated
between hematocrit and blood pressure in patients with end-
stage renal failure [5] and in dialysis patients [42]. The influence
of pre-existing hypertension on the blood pressure reactivity to
changes in hematocrit has been extended further in animal
studies, where spontaneously hypertensive rats demonstrate a
fall in blood pressure with lowering of hematocrit but normoten-
sive controls show no change [43].
The present study suggests there is a difference in the
vascular response to oxygen breathing between patients who
maintain a stable blood pressure following correction of anemia
(Group 1) and those in whom blood pressure increases (Group
2). The patients in Group 2 demonstrated a fall in forearm blood
flow and an accompanying rise in vascular resistance associated
with increased oxygen tension produced by breathing supple-
mentary oxygen. These results suggest that those patients liable
to develop or worsen hypertension during rHuEPO therapy
may have heightened reactivity to an increase in the partial
pressure of oxygen in the blood and hence in the tissues. It
should be stressed that the difference in FVR appears to be due
to altered vascular response to the increase in oxygen tension,
not the increased P°2 itself, as there was no difference in the
size of the increment of oxygen carriage between the two
groups.
Thus, our present findings indicate that blood pressure re-
sponders exhibit a greater degree of hypoxic vasodilatation
before correction of anemia than those in whom blood pressure
remains stable. However, it is uncertain why the blood pressure
responders should have a heightened vascular responsiveness
to increased arterial partial pressure of oxygen (PaO2). After
anemia was corrected, several other factors may have contrib-
uted to the increase in FVR found in both groups. As similar
increases in hemoglobin occurred, whole blood viscosity would
have risen correspondingly. It is also possible that prolonged
improvement in tissue oxygenation resulted in structural mod-
ification to the vascular bed rather than short-term alterations in
vascular smooth muscle tone [44]. However, it was of interest
that a significant fall in pH was seen between arterial and
venous blood in the group with stable blood pressure, but not in
the Group 2 patients. This may reflect an underlying difference
in the metabolic profile in the two groups. When supplementary
oxygen was administered, the difference in pH disappeared. A
larger proportion of patients in Group 2 had a past history of
hypertension, but basal blood flow and FVR were similar in the
blood pressure responders and non-responders.
In summary, forearm vascular resistance is increased in
response to correction of uremic anemia, both by administra-
tion of supplementary oxygen and by correction of anemia with
rHuEPO therapy. The responses of forearm blood flow and
vascular resistance to 02 breathing differed between patients
who maintained a stable blood pressure during the treatment
period and those who increased their blood pressure. The
variation between patients in loss of hypoxic vasodilation—or
rather, the exaggerated increase in vascular resistance in the
latter group—may contribute to the explanation of recombinant
human erythropoietin-induced hypertension.
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